Actively Recruiting
Observational Study on Long-Term Use of Odevixibat in Patients With Alagille Syndrome
Led by Ipsen · Updated on 2026-10-23
30
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are observing patients with Alagille syndrome ALGS, a rare liver disease that causes itching, as they use the medicine odevixibat Bylvay in their everyday lives. This study focuses on evaluating the long-term effectiveness and safety of odevixibat in those who are receiving ongoing treatment for ALGS. It is an observational study sponsored by Ipsen. Participants in this study are patients with ALGS who are currently on or starting treatment with odevixibat. The study collects data over about five years to see how well patients do on this medicine in real-world settings. There are no experimental interventions rather, patients continue their usual treatment with odevixibat while the study gathers information about their health outcomes. During the study, participants will be monitored regularly to observe key outcomes such as the percentage undergoing biliary diversion surgery or liver transplantation, survival without surgery or transplant, overall survival, and changes in weight and height. Safety is also tracked by recording adverse events related to vitamin deficiencies, liver toxicity, bleeding, and other possible side effects. Data collection continues for approximately five years, with safety monitoring extending 180 days after the last dose of odevixibat.
CONDITIONS
Brief Title
A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
Research Team
I
Ipsen Recruitment Enquiries
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here